{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:11:01Z","timestamp":1790061061161,"version":"4.0.1"},"reference-count":33,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"vor","delay-in-days":276,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"funder":[{"name":"TI Food and Nutrition","award":["CH001"],"award-info":[{"award-number":["CH001"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4,1]]},"abstract":"<jats:p>Obesity is associated with an increased risk for the development of type 2 diabetes and vascular complications. Advanced glycation end products are increased in adipose tissue and have been associated with insulin resistance, vascular dysfunction, and inflammation of adipose tissue. Here, we report that delayed intervention with pyridoxamine (PM), a vitamin B6 analog that has been identified as an antiglycating agent, protected against high-fat diet (HFD)\u2013induced body weight gain, hyperglycemia, and hypercholesterolemia, compared with mice that were not treated. In both HFD-induced and db\/db obese mice, impaired glucose metabolism and insulin resistance were prevented by PM supplementation. PM inhibited the expansion of adipose tissue and adipocyte hypertrophy in mice. In addition, adipogenesis of murine 3T3-L1 and human Simpson-Golabi-Behmel Syndrome preadipocytes was dose- and time-dependently reduced by PM, as demonstrated by Oil Red O staining and reduced expression of adipogenic differentiation genes. No ectopic fat deposition was found in the liver of HFD mice. The high expression of proinflammatory genes in visceral adipose tissue of the HFD group was significantly attenuated by PM. Treatment with PM partially prevented HFD-induced mild vascular dysfunction. Altogether, these findings highlight the potential of PM to serve as an intervention strategy in obesity.<\/jats:p>","DOI":"10.2337\/db15-1390","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T03:43:57Z","timestamp":1451533437000},"page":"956-966","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":65,"title":["Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet\u2013Induced Obese Mice"],"prefix":"10.2337","volume":"65","author":[{"given":"Dionne E.","family":"Maessen","sequence":"first","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Brouwers","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien H.","family":"Gaens","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiaan","family":"Wouters","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack P.","family":"Cleutjens","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Pathology, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Janssen","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Pharmacology, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Miyata","sequence":"additional","affiliation":[{"name":"United Centers for Advanced Research and Translational Medicine, Tohoku University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen D.","family":"Stehouwer","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper G.","family":"Schalkwijk","sequence":"additional","affiliation":[{"name":"CARIM School for Cardiovascular Diseases, Maastricht University Medical Center, Maastricht, the Netherlands"},{"name":"Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,12,30]]},"reference":[{"key":"2022031300502669700_B1","doi-asserted-by":"crossref","first-page":"T47","DOI":"10.1530\/JOE-13-0339","article-title":"Adipocytokines in obesity and metabolic disease","volume":"220","author":"Cao","year":"2014","journal-title":"J Endocrinol"},{"key":"2022031300502669700_B2","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1161\/ATVBAHA.113.302281","article-title":"N\u03b5-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance","volume":"34","author":"Gaens","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022031300502669700_B3","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2337\/db13-1636","article-title":"RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice","volume":"63","author":"Song","year":"2014","journal-title":"Diabetes"},{"key":"2022031300502669700_B4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1055\/s-0028-1082085","article-title":"Modulation of insulin action by advanced glycation endproducts: a new player in the field","volume":"40","author":"Schalkwijk","year":"2008","journal-title":"Horm Metab Res"},{"key":"2022031300502669700_B5","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.2337\/diabetes.54.8.2314","article-title":"Insulin resistance and type 2 diabetes in high-fat-fed mice are linked to high glycotoxin intake","volume":"54","author":"Sandu","year":"2005","journal-title":"Diabetes"},{"key":"2022031300502669700_B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1042\/bj3440109","article-title":"Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose","volume":"344","author":"Thornalley","year":"1999","journal-title":"Biochem J"},{"key":"2022031300502669700_B7","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00726-010-0779-9","article-title":"Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics","volume":"42","author":"Schalkwijk","year":"2012","journal-title":"Amino Acids"},{"key":"2022031300502669700_B8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/bbrc.1996.0366","article-title":"Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine","volume":"220","author":"Booth","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"2022031300502669700_B9","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00018-005-5082-7","article-title":"Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage","volume":"62","author":"Voziyan","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"2022031300502669700_B10","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/dom.12058","article-title":"Current therapeutic interventions in the glycation pathway: evidence from clinical studies","volume":"15","author":"Engelen","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031300502669700_B11","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1159\/000108104","article-title":"Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy","volume":"27","author":"Williams","year":"2007","journal-title":"Am J Nephrol"},{"key":"2022031300502669700_B12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1681\/ASN.2011030272","article-title":"Pyridorin in type 2 diabetic nephropathy","volume":"23","author":"Lewis","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022031300502669700_B13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1515\/cclm-2012-0878","article-title":"Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen","volume":"52","author":"Scheijen","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"2022031300502669700_B14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1006\/abio.1993.1229","article-title":"The assay of S-D-lactoylglutathione in biological systems","volume":"211","author":"McLellan","year":"1993","journal-title":"Anal Biochem"},{"key":"2022031300502669700_B15","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1101\/gad.10.9.1096","article-title":"ADD1\/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism","volume":"10","author":"Kim","year":"1996","journal-title":"Genes Dev"},{"key":"2022031300502669700_B16","doi-asserted-by":"crossref","first-page":"5495","DOI":"10.1128\/MCB.19.8.5495","article-title":"Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1\/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism","volume":"19","author":"Fajas","year":"1999","journal-title":"Mol Cell Biol"},{"key":"2022031300502669700_B17","doi-asserted-by":"crossref","first-page":"e0119587","DOI":"10.1371\/journal.pone.0119587","article-title":"Accumulation of advanced glycation end-products and activation of the SCAP\/SREBP Lipogenetic pathway occur in diet-induced obese mouse skeletal muscle","volume":"10","author":"Mastrocola","year":"2015","journal-title":"PLoS One"},{"key":"2022031300502669700_B18","doi-asserted-by":"crossref","first-page":"G398","DOI":"10.1152\/ajpgi.00450.2012","article-title":"Advanced glycation end products promote hepatosteatosis by interfering with SCAP-SREBP pathway in fructose-drinking mice","volume":"305","author":"Mastrocola","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2022031300502669700_B19","doi-asserted-by":"crossref","first-page":"F236","DOI":"10.1152\/ajprenal.00646.2010","article-title":"Advanced glycation end products (AGEs) increase human mesangial foam cell formation by increasing Golgi SCAP glycosylation in vitro","volume":"301","author":"Yuan","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031300502669700_B20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cca.2013.02.003","article-title":"Adipokines in obesity","volume":"419","author":"Leal","year":"2013","journal-title":"Clin Chim Acta"},{"key":"2022031300502669700_B21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1196\/annals.1433.042","article-title":"Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endothelial function and adipokines","volume":"1126","author":"Stirban","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"2022031300502669700_B22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/MOL.0b013e32835aea13","article-title":"Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity","volume":"24","author":"Gaens","year":"2013","journal-title":"Curr Opin Lipidol"},{"key":"2022031300502669700_B23","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/eurheartj\/eht402","article-title":"Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype","volume":"35","author":"Hanssen","year":"2014","journal-title":"Eur Heart J"},{"key":"2022031300502669700_B24","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.metabol.2009.02.033","article-title":"Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL\/6J mice","volume":"58","author":"Hagiwara","year":"2009","journal-title":"Metabolism"},{"key":"2022031300502669700_B25","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/092986610791760423","article-title":"Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice","volume":"17","author":"Unoki-Kubota","year":"2010","journal-title":"Protein Pept Lett"},{"key":"2022031300502669700_B26","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.molmet.2013.11.006","article-title":"Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms","volume":"3","author":"Stirban","year":"2014","journal-title":"Mol Metab"},{"key":"2022031300502669700_B27","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.exger.2011.02.001","article-title":"Pyridoxamine prevents age-related aortic stiffening and vascular resistance in association with reduced collagen glycation","volume":"46","author":"Wu","year":"2011","journal-title":"Exp Gerontol"},{"key":"2022031300502669700_B28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1523-1755.2002.00207.x","article-title":"Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat","volume":"61","author":"Degenhardt","year":"2002","journal-title":"Kidney Int"},{"key":"2022031300502669700_B29","first-page":"655","article-title":"Synergistic effects of telmisartan and pyridoxamine on early renal damage in spontaneously hypertensive rats","volume":"5","author":"Zhu","year":"2012","journal-title":"Mol Med Rep"},{"key":"2022031300502669700_B30","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ndt\/gfm589","article-title":"Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats","volume":"23","author":"Waanders","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2022031300502669700_B31","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1046\/j.1523-1755.2003.00027.x","article-title":"The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats","volume":"63","author":"Alderson","year":"2003","journal-title":"Kidney Int"},{"key":"2022031300502669700_B32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.metabol.2006.08.026","article-title":"Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)\/Ta mice","volume":"56","author":"Tanimoto","year":"2007","journal-title":"Metabolism"},{"key":"2022031300502669700_B33","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/AJP.0b013e318272ebec","article-title":"Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study","volume":"29","author":"Garg","year":"2013","journal-title":"Clin J Pain"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/diabetes.diabetesjournals.org\/syndication\/doi\/10.2337\/db15-1390","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/65\/4\/956\/581727\/db151390.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/65\/4\/956\/581727\/db151390.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:48:43Z","timestamp":1667407723000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/65\/4\/956\/35103\/Delayed-Intervention-With-Pyridoxamine-Improves"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,30]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,12,30]]},"published-print":{"date-parts":[[2016,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db15-1390","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,30]]}}}